BIOLASE, Inc. Revised Earnings Guidance for the Fourth Quarter Ended December 31, 2012
January 07, 2013 at 08:30 am EST
Share
BIOLASE, Inc. revised earnings guidance for the fourth quarter ended December 31, 2012. The company announced that, based on a preliminary review of its financial performance for the fourth quarter ended December 31, 2012, the company expects to exceed its previous guidance and report net revenue in excess of $18 million.
BIOLASE, Inc. is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company's systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. It offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems. The Company's all-tissue Waterlase dental laser systems consist of its flagship Waterlase iPlus, Waterlase Express, and Waterlase MDX. Its soft tissue diode laser systems consist of the Epic X, Epic Hygiene, Epic Q, and Epic 10 diode lasers that perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and provide temporary pain relief. Epic X, and Epic 10 systems feature its 940 nanometer wavelength with patented pulse technology called ComfortPulse.
BIOLASE, INC. 
